Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Tirzepatide is a 39-amino-acid dual agonist that binds both the GIP and GLP-1 receptors from a single peptide backbone, with a C20 fatty-diacid moiety that extends its half-life in solution. Supplied as a sterile lyophilised powder, verified to ≥98% purity by RP-HPLC and confirmed by mass spectrometry. All three vial sizes are held in UK stock and dispatch same working day on orders placed before 2pm.
In vitro, Tirzepatide is used to characterise co-activation of the GIP and GLP-1 receptors — including cAMP accumulation, β-arrestin recruitment and receptor-bias studies. It is often used as a comparator peptide when characterising newer molecules such as Retatrutide or Cagrilintide combinations.
Tirzepatide is a 39-amino-acid dual agonist that binds both the GIP and GLP-1 receptors from a single peptide backbone, with a C20 fatty-diacid moiety that extends its half-life in solution. Supplied as a sterile lyophilised powder, verified to ≥98% purity by RP-HPLC and confirmed by mass spectrometry. All three vial sizes are held in UK stock and dispatch same working day on orders placed before 2pm.
In vitro, Tirzepatide is used to characterise co-activation of the GIP and GLP-1 receptors — including cAMP accumulation, β-arrestin recruitment and receptor-bias studies. It is often used as a comparator peptide when characterising newer molecules such as Retatrutide or Cagrilintide combinations.